VivoSeq
Other

Recurrent or Refractory

0

Pipeline Programs↗

8

Active Trials↗

8

Companies Involved↗

Recurrent or Refractory is an early-stage landscape with 0 programs across 8 companies. The most active players are Gynecologic Oncology Group, Bayer, Roche.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

70/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalS

South Plains Oncology Consortium

0 programs

PreclinicalA

Astex Pharmaceuticals, Inc.

0 programs

PreclinicalM

Matrix Pharmaceutical

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

39

clinical trials

Completed19 · 49%
Recruiting6 · 15%
Terminated6 · 15%
Unknown status4 · 10%
Active, not recruiting2 · 5%
Withdrawn2 · 5%

Clinical Trials

Trial Activity

39 trials

A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Recruiting·CCullgen (Shanghai),Inc·Phase 1·NCT07347171·45 enrolled
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03911388·24 enrolled
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Recruiting·—·Phase 2·NCT04906096·25 enrolled
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT05366179·36 enrolled
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
Recruiting·—·Phase 1·NCT04510051·18 enrolled
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
Recruiting·Incyte logoIncyte·Phase 1/2·NCT06843408·30 enrolled
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Active, not recruiting·SStanford University·Phase 1·NCT03233854·56 enrolled
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
Active, not recruiting·LLoyola University·Phase 1·NCT04214886·24 enrolled
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
Completed·—·Phase 1·NCT06354387·5 enrolled
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Completed·Bayer logoBayer·Phase 1·NCT02085148·62 enrolled
Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
Completed·—·Phase 2·NCT03660761·25 enrolled
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT01614795·46 enrolled
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Completed·SSeattle Children's Hospital·Phase 1·NCT03638167·11 enrolled
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Completed·National Cancer Institute (NCI)·Phase 1·NCT02315612·134 enrolled
Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas
Completed·National Cancer Institute (NCI)·Phase 2·NCT00003745·125 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)